QAS.AI delivers real-time AI based decision support to assist neuroendovascular procedures—improving safety, precision, and outcomes for patients with complex cerebrovascular disease.
How It Works
From Angiography to Action in Under one Second
QAS.AI analyzes post-device angiograms in real time to forecast treatment success—predicting aneurysm occlusion at six months based on flow dynamics immediately after device placement.
In acute stroke, the system quantifies distal perfusion and provides automated mTICI scores following thrombectomy, with potential for deeper recanalization analytics.
Powered by thousands of annotated cases, QAS.AI delivers prognostic insight during the procedure—in under one second.
Key Benefits
Automated Aneurysm Detection
QAS.AI identifies aneurysms on any contrast-filled angiogram—pre- or post-device—highlighting them in real time with no manual input.
Standardized Data, Personalized Insight
Probability of successful treatment
68.52%
Outcome-Focused Guidance
Built for the Procedure Room
Adapt Instantly
With real-time occlusion probability, interventionalists can make informed decisions mid-procedure—adjusting device choice, repositioning, or strategy on the spot.
Seamless Workflow
QAS.AI integrates directly into angiographic imaging—providing feedback without disrupting flow, extending case time, or requiring additional steps.
Confidence in Diagnosis
With a 90%+ accuracy in lesion localization and inlet detection, QAS.AI reduces uncertainty and helps eliminate misdiagnoses due to imaging variability.
Scaling the Platform, Expanding the Impact
Expanded Indications
Our platform is evolving to support other flow-driven conditions including intracranial atherosclerosis, AVMs, and ischemic stroke.
Integrated Partnerships
Collaborations with imaging vendors and platform providers are enabling seamless integration across diverse clinical and surgical ecosystems
Ongoing Clinical Validation
Multi-center clinical studies are underway to validate QAS.AI as a predictive and diagnostic standard—accelerating regulatory pathways and clinical adoption.
Our Partners
